Meeting
2011 ASCO Annual Meeting
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Authors
R. S. Finn
University of California, Los Angeles, Los Angeles, CA
R. S. Finn , R. T. P. Poon , T. Yau , H. Klumpen , L. Chen , Y. Kang , T. Kim , C. Gomez-Martin , C. Rodriguez-Lope , T. Kunz , T. Paquet , K. Asubonteng , R. E. Winkler , O. Anak , D. B. Sellami , J. Bruix
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT 00828594
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4074)
Abstract #
4074
Poster Bd #
31H
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
First Author: Changhoon Yoo
Poster
2014 ASCO Annual Meeting
A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2014 Gastrointestinal Cancers Symposium
A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2013 Gastrointestinal Cancers Symposium
A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
First Author: Takuji Okusaka